Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review.
暂无分享,去创建一个
H. Collard | J. Leipsic | C. Ryerson | C. Hague | Harold R Collard | Pearce G Wilcox | Jonathon Leipsic | P. Wilcox | Christopher J Ryerson | Cameron J Hague | D. Assayag | Tiffany A Winstone | Deborah Assayag | James V Dunne | J. Dunne
[1] G. La Torre,et al. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease , 2012, The clinical respiratory journal.
[2] T. Medsger,et al. Severe restrictive lung disease in systemic sclerosis. , 1994, Arthritis and rheumatism.
[3] D. Hansell,et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression , 2010, European Respiratory Journal.
[4] J. Pope,et al. Determinants of morbidity and mortality of systemic sclerosis in Canada. , 2010, Seminars in arthritis and rheumatism.
[5] R. D. du Bois,et al. Exercise peripheral oxygen saturation (Spo2) accurately reflects arterial oxygen saturation (Sao2) and predicts mortality in systemic sclerosis , 2009, Thorax.
[6] H. Collard,et al. Prevalence and prognosis of unclassifiable interstitial lung disease , 2012, European Respiratory Journal.
[7] R. Domsic,et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. , 2009, Arthritis and rheumatism.
[8] T. Medsger,et al. Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.
[9] C. Fanali,et al. β-thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up , 2011, Respiratory research.
[10] D. Lynch,et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. , 2008, Chest.
[11] L. Rubin. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[12] P. Grenier,et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. , 2006, Arthritis and rheumatism.
[13] A. Nicholson,et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. , 2002, American journal of respiratory and critical care medicine.
[14] D. Hansell,et al. Interstitial lung disease in systemic sclerosis: a simple staging system. , 2008, American journal of respiratory and critical care medicine.
[15] A. Nicholson,et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. , 2002, American journal of respiratory and critical care medicine.
[16] M. Remy-Jardin,et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. , 2006, The Journal of rheumatology.
[17] Joyce S Lee,et al. A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis , 2012, Annals of Internal Medicine.
[18] Musellim Benan,et al. The natural course of progressive systemic sclerosis patients with interstitial lung involvement , 2007, Clinical Rheumatology.
[19] N. Prandini,et al. Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters , 2011, Rheumatology International.
[20] B. White. Interstitial lung disease in scleroderma. , 2003, Rheumatic diseases clinics of North America.
[21] D. Hansell,et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. , 2007, Arthritis and rheumatism.
[22] A. Lopes,et al. Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over a five-year period. , 2011, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.
[23] K. Lee,et al. Interstitial Pneumonia in Progressive Systemic Sclerosis: Serial High-Resolution CT Findings with Functional Correlation , 2001, Journal of computer assisted tomography.
[24] A. Nicholson,et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. , 2003, American journal of respiratory and critical care medicine.
[25] G. Raghu,et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.
[26] T. E. King,et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease , 2009, European Respiratory Journal.
[27] B. Thiers. Cyclophosphamide versus Placebo in Scleroderma Lung Disease , 2007 .
[28] R. Scorza,et al. T-889C IL-1α promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis , 2006, Clinical Rheumatology.
[29] R. Elashoff,et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. , 2008, American journal of respiratory and critical care medicine.
[30] M. Humbert,et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. , 2011, Chest.
[31] Chi-Hong Tseng,et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. , 2011, Arthritis and rheumatism.
[32] Jonathan G. Goldin,et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. , 2011, Arthritis and rheumatism.